The efficiency of the PD-1/PD-L1 inhibitors is related to the PD-L1 expression, and/or tumor mutation burden (TMB) in tumor cells (Topalian et al., 2012; Rosenberg et al., 2016; Yarchoan et al., 2017; Hellmann et al., 2018a; Hellmann et al., 2018b; Hellmann et al., 2018c; Rizvi et al., 2018; Keenan et al., 2019). Here, CD274 is linked to neoplasm.